Live Breaking News & Updates on Institutional Perspectives|Page 2

Stay updated with breaking news from Institutional perspectives. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Research Developments Provide Clarity and Raise Further Questions in Myeloma, Myelofibrosis, DLBCL, and MDS

Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more. ....

Mayo Clinic In Rochester , United States , Muhamad Alhaj Moustafa , Sikander Ailawadhi , Naseema Gangat , Talha Badar , Ricardod Parrondo , Institutional Perspectives , Mayo Clinic , Onclive Institutional Perspectives In Cancer , Fda Approval Of Ivosidenib , Fda Approval Of Momelotinib ,

Combination Regimens Expand RCC and Prostate Cancer Treatment Armamentariums

Bupath highlights key points on the evolving standards of care in first- and second-line RCC; the role of PARP inhibitors in prostate cancer; and the potential uses for next-generation hormonal agents plus androgen deprivation therapy in frontline metastatic hormone-sensitive prostate cancer. ....

United States , Mike Lattanzi , Uchealth Tony Grampsas , Benjamin Garmezy , Elizabeth Kessler , Manojkumar Bupathi , Mountain Cancer Centers In Littleton , Sarah Cannon Research Institute In Nashville , Institutional Perspectives , Rocky Mountain Cancer Centers , Sarah Cannon Research Institute , Tony Grampsas Urologic Cancer Care Clinic , Anschutz Medical Campus , Texas Oncology , Austin Central , Renal Cell Carcinoma , Parp Inhibitor Based Combinations , Prostate Cancer ,

State of the Science Summit - Lung Cancer: Chaired by Joshua K Sabari, MD

State of the Science Summit - Lung Cancer: Chaired by Joshua K Sabari, MD ....

Joshuak Sabari , Salmanr Punekar , Joshua Sabari , Perlmutter Cancer Center , Langone Health , Science Summit , Science Summits , Institutional Perspectives , Breast Cancer , Lung Cancer , Onclive On Air , Nyu Langone Health , Nyu Perlmutter Cancer Center ,

Institutional Perspectives in Cancer - Hematologic Malignancies: Chaired by Catherine Coombs, MD

Institutional Perspectives in Cancer - Hematologic Malignancies: Chaired by Catherine Coombs, MD ....

Nirav Shah , Angela Fleischmann , Swetha Kambhampati , Catherine Coombs , Joshua Zeidner , Institutional Perspectives , Science Summits , Breast Cancer , Lung Cancer , New Treatment Options , Acute Myeloid , Standards Been Challenged , Combination Studies , Onclive On Air , Updated Classification And New Treatment Options For Acute Myeloid Leukemia , Have Standards Been Challenged In Myelofibrosis , Emerging Treatments In Dlbcl , New Directions And Combination Studies In Cll , Treatment Crossroads Sequencing Btk Inhibitors In Mcl ,

ADCs and Immunotherapy Are Redefining Urothelial Cancer Treatment

Bupathi highlights key points that were presented at an OncLive Institutional Perspectives in Cancer, including implications of the EV-302 trial findings; data updates from the phase 1/2 ICRA trial; and future directions for urothelial cancer. ....

United States , Manojkumar Bupathi , Mountain Cancer Centers In Littleton , Institutional Perspectives , Rocky Mountain Cancer Centers , Enfortumab Vedotin , Urothelial Carcinoma , Targeted Therapy , Ev 302 Trial , Icra Trial ,